Discover comprehensive details about Evolocumab, including its pronunciation, uses, dosage instructions, indications, and guidelines on how and when to take it or avoid it. The updated prescription ...

The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial in ...

Please provide your email address to receive an email when new articles are posted on . CV benefits of PCSK9 inhibition with evolocumab may be stronger in patients with autoimmune or inflammatory ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of ...

The addition of evolocumab to the standard background therapy for patients with atherosclerotic cardiovascular disease (ASCVD) would exceed the typically accepted range of cost-effectiveness, ...

The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to ...

THOUSAND OAKS, CA — Treating statin-intolerant patients with evolocumab (Amgen, Thousand Oaks, CA) significantly lowers LDL-cholesterol levels, according to the top-line results of the GAUSS-2 study ...

WASHINGTON, DC (UPDATED)—The eagerly anticipated final results of FOURIER, a large clinical trial testing evolocumab (Repatha, Amgen) in patients with stable atherosclerotic cardiovascular disease, ...

Review the side-effects of Evolocumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

Please provide your email address to receive an email when new articles are posted on . Pretreatment evolocumab did not lower risk for periprocedural microvascular dysfunction in patients undergoing ...

PCSK9 inhibition with evolocumab was safe and more effective than statin monotherapy in reducing LDL-C in stable individuals with moderate CKD and clinically evident atherosclerosis. Evolocumab used ...

The PCSK9 inhibitor evolocumab (Repatha, Amgen) is far too expensive to make economic sense for the healthcare system and private payers, according to the results of yet another cost-effectiveness ...